Abstract 1826P
Background
The global incidence of breast cancer is increasing, highlighting the need for attention not only to treatment but also to long-term survivorship issues. Osteoporosis, an age-related bone disorder, presents a significant concern for patients with breast cancer due to its potential impact on morbidity and mortality. This Korean nationwide cohort study aimed to investigate the occurrence and risk factors of osteoporosis among patients with breast cancer, with a specific focus on gender disparities.
Methods
Using data from the Korean National Health Insurance claim database, we identified individuals diagnosed with ductal carcinoma in situ or breast cancer as their primary diagnosis between 2009 and 2015. Patients diagnosed with osteoporosis were determined based on ICD-10 codes (International Classification of Disease) and medication prescriptions. Propensity score matching was performed to minimize confounding variables.
Results
Among 299 male and 80362 female breast cancer patients, a higher prevalence of osteoporosis was observed in females (n=13423(16.7%) vs n=15(5.0%)). Endocrine therapy was associated with an increased risk of osteoporosis, particularly among females (HR 6.37, 95%CI, 3.74-10.89, p<0.001). Age, steroid medication use, and comorbidity burden were also identified as significant risk factors for osteoporosis. Adjusting other variables, females diagnosed with osteoporosis had a higher incidence of only hip or vertebral fractures compared to males (HR 3.96, 95%CI, 1.24-12.64, p=0.020). While overall fracture incidence was higher in males before matching, gender differences were not significant after propensity score matching.
Conclusions
In conclusion, our study highlights the importance of proactive screening and management of osteoporosis in breast cancer patients, with a focus on gender-specific risk factors. These findings emphasize the necessity of comprehensive bone health assessment and preventive measures to improve long-term outcomes and quality of life for breast cancer survivors. Further research is warranted to elucidate the underlying mechanisms of gender differences in osteoporosis risk and evaluate the effectiveness of targeted interventions in this population.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1885P - Serum ATG5 protein may determine chemotherapy-related cognitive dysfunction in older patients with cancer
Presenter: Ozgur Tanriverdi
Session: Poster session 12
1886P - Expectations and priorities of older patients with cancer: The PRIORITY multicenter cohort study
Presenter: Thomas Grellety
Session: Poster session 12
1887P - Effect of logotherapy on chronic sorrow, dignity, and meaning in life of palliative care patients
Presenter: Yasemin Eskigulek
Session: Poster session 12
1888P - PalliScore: Validation of a rapid scoring system for enhancing decision-making in the Emergency Department for cancer patients in palliative care
Presenter: Rafael Carmo
Session: Poster session 12
1889P - Addressing unmet needs in the management of persistent severe cancer pain: European expert recommendations
Presenter: Mario di Palma
Session: Poster session 12
1890P - End-of-Life (EOL) systemic anticancer treatment (SACT) and health services use before and during the COVID-19 pandemic
Presenter: Javaid Iqbal
Session: Poster session 12
1891P - The effects of glucagon-like peptide 1 agonists on immune checkpoint inhibitor-associated cardiotoxicity
Presenter: Cho Han Chiang
Session: Poster session 12
1892P - Glucagon-like peptide 1 agonists and anthracycline-associated cardiotoxicity in hematologic malignancies
Presenter: Cho Hung Chiang
Session: Poster session 12
1893P - Incidence of myocardial ischemia during treatment with capecitabine: Assessment with Holter recording and cardiac biomarkers
Presenter: Anne Dyhl-Polk
Session: Poster session 12
1894P - Pulmonary function test (PFT) and circulating biomarkers in immune-related pneumonitis (irP) in advanced non-small cell lung cancer (aNSCLC): A real-world multidisciplinary experience
Presenter: Loc Carlo Bao
Session: Poster session 12